Use of Dexibuprofen and Levocetirizine Sustained-release Double-Layer Tablets in the Treatment of Airway Inflammation

A levocetirizine and airway inflammation technology, applied in the field of pharmacy, can solve the problems of restricting the application of new compositions, no research reports on compound preparations on the market, and the curative effect can not fully meet the clinical needs, etc., to reduce leukocyte exudation and aggregation, relieve alveolar collapse and atelectasis, and inhibit nasal mucosal inflammation

Inactive Publication Date: 2011-11-30
XIAN LIJUN PHARMA CO LTD
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as a non-steroidal anti-inflammatory drug, nimesulide has been reported with increasing adverse reactions in recent years, leading to the delisting of products containing nimesulide in many countries, which limits the application of this new composition
[0026] As mentioned above, there are clinical

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Dexibuprofen and Levocetirizine Sustained-release Double-Layer Tablets in the Treatment of Airway Inflammation
  • Use of Dexibuprofen and Levocetirizine Sustained-release Double-Layer Tablets in the Treatment of Airway Inflammation
  • Use of Dexibuprofen and Levocetirizine Sustained-release Double-Layer Tablets in the Treatment of Airway Inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Embodiment 1: Preparation of Dexibuprofen and Levocetirizine Sustained-release Double-Layer Tablets

[0074] Prescription (1000 tablets)

[0075] Immediate Release Layer Prescription

Dexibuprofen

45g

Levocetirizine dihydrochloride

2.5g

lactose

25g

microcrystalline cellulose

25g

compressible starch

50g

Crospovidone

12g

8% povidone K30 in 95% ethanol solution

Appropriate amount

silica

1g

Magnesium stearate

1g

Extended Release Layer Prescription

Dexibuprofen (or its pharmaceutically acceptable salt)

180g

Hydroxypropyl Methyl Cellulose K4m

15g

Calcium hydrogen phosphate

30g

compressible starch

18g

Food coloring (such as sunset yellow aluminum tint, etc.)

Appropriate amount

Tween 80

Appropriate amount

8% polyvinylpyrrolidone 80% ethanol solution

Appropriate a...

Embodiment 2

[0079] Example 2: Effect of Dexibuprofen and Levocetirizine Sustained-release Double-Layer Tablets on Paw Swelling of Rats Induced by Carrageenan

[0080] 1) Preparation of paw swelling model in rats induced by carrageenan

[0081] Rats were randomly divided into 9 groups according to body weight, 8 rats in each group, respectively 0.5% sodium carboxymethylcellulose solution group (negative control), and the other 8 groups were drug treatment groups. After intragastric administration for 1 hour, the volume of the left hind paw of the rats was measured by the volumetric method (UGO BASILE Company, Italy, 7140 volume measuring instrument). Then 0.1ml of 1% carrageenan was subcutaneously injected into the left hind paw, and then the volume of the left hind paw was measured 1, 2, 3, and 4 hours after the injection. Calculate the swelling value (the difference between the volume after inflammation and the volume before inflammation), and compare the difference of swelling value be...

Embodiment 3

[0086] Example 3: Effect of Dexibuprofen and Levocetirizine Sustained-release Double-Layer Tablets on the Swelling Degree of Otitis in Mice

[0087] 1) Preparation of mouse auricular xylene-induced inflammation model

[0088] The mice were randomly divided into 9 groups, 10 mice in each group. They were 0.5% sodium carboxymethylcellulose solution group (negative control), and the other 8 groups were drug treatment groups. 30 minutes after intragastric administration, all mice were coated with appropriate amount of xylene (about 0.1ml) with cotton swabs on the front and back sides of the right ear of the tested mice to cause inflammation. After 4 hours of inflammation, the mice were sacrificed by devertebral dislocation, and the two ears were cut off along the baseline of the auricle. Use a 7mm diameter punch to punch the left and right ear pieces in the same part of the two ears respectively. Weigh and record the weights of the left and right slices with a micro electronic ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Hardnessaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a use of a dexibuprofen levocetirizine double-layer sustained release tablet in treatment of airway inflammation. The tablet is composed of two layers, wherein one layer is the rapid-release part, composed of dexibuprofen, levocetirizine dihydrochloride and a pharmaceutically acceptable rapid-release additive; the other layer is the sustained-release part, composed of dexibuprofen and a pharmaceutically acceptable sustained-release additive.

Description

Technical field: [0001] The invention relates to the field of pharmacy, in particular to the application of a dexibuprofen levocetirizine slow-release double-layer tablet in alleviating various discomfort symptoms caused by airway inflammation. Background technique: [0002] Airway inflammation (Airway Inflammation), including upper and lower respiratory tract inflammation, is the most important pathological change of many respiratory diseases. The upper respiratory tract inflammation mainly refers to the inflammation caused by rhinitis, sinusitis, tonsillitis, adenoiditis and laryngitis, and the lower respiratory tract inflammation mainly refers to the acute and chronic pneumonia, tracheitis, bronchitis and bronchial asthma. inflammation. Since the parts of the upper and lower respiratory tracts are anatomically continuous, inflammation is rarely limited to a certain part. Various experimental and clinical studies have confirmed that the inflammatory responses of the upper...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/495A61K9/24A61P11/00A61P29/00A61P9/14A61P11/02A61K31/192
CPCA61K9/2086A61P9/14A61P11/00A61P11/02A61P29/00
Inventor 熊晓云苏建英高湘宜冰丁倩周云李建育
Owner XIAN LIJUN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap